Ob.Gyn. NewsFDA expands approval of fulvestrant for HR+/HER2– advanced breast cancerAugust 30, 2017Breast Cancer
Ob.Gyn. NewsAnnual mammograms from age 40 linked with greatest reductions in mortalityAugust 28, 2017Breast Cancer
Ob.Gyn. NewsFDA approves neratinib for extended adjuvant treatment of HER2+ breast cancerJuly 18, 2017Breast Cancer
Ob.Gyn. NewsUse of Pap smears, mammography on the declineJuly 13, 2017GynecologyPreventive CarePractice ManagementBreast CancerGynecologic CancerBusiness of Medicine
Ob.Gyn. NewsConsequence of change? Medicaid disenrollment delayed breast cancer diagnosisJuly 5, 2017Breast CancerBusiness of Medicine
Ob.Gyn. NewsSome adjuvant endocrine therapies better than others for young breast cancer patientsJuly 5, 2017Breast Cancer
Ob.Gyn. NewsLow-fat diet reduces risk of death if breast cancer is diagnosedJuly 5, 2017Breast CancerPreventive Care
Ob.Gyn. NewsQuality of life preserved with ribociclib + letrozole for advanced breast cancerJuly 3, 2017Breast Cancer
Ob.Gyn. NewsSOLE trial: Intermittent letrozole may provide benefit for some breast cancer patientsJune 29, 2017Breast Cancer
Ob.Gyn. NewsACOG recommends women start mammography between ages 40 and 50 yearsJune 22, 2017Breast CancerGynecology
Ob.Gyn. NewsVIDEO: Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2017June 20, 2017Breast Cancer
Ob.Gyn. NewsShort-HER trial: DFS is similar, cardiac toxicity lower with short trastuzumab courseJune 16, 2017Breast Cancer
Ob.Gyn. NewsVIDEO: Metastatic Trial Search links MBC patients to relevant trialsJune 14, 2017Breast Cancer
Ob.Gyn. NewsOlympiAD’s positive results spell good news for olaparib in breast cancerJune 8, 2017Breast Cancer
Ob.Gyn. NewsVIDEO: Olaparib improves outlook in women with BRCA-related HER2-negative MBCJune 4, 2017Breast Cancer
